Pfizer Delays Major M&A As It Awaits U.S. Tax Reform Clarity
Pfizer Inc's (PFE.N) chief executive said on Tuesday he would prefer to wait for clarity on U.S. tax reform before engaging in any big deals in order to get a better understanding of any potential acquisition target's value.
The largest U.S. drugmaker has been under increasing pressure from investors and Wall Street to pull off a large deal to help reignite growth.
The largest U.S. drugmaker has been under increasing pressure from investors and Wall Street to pull off a large deal to help reignite growth.